Veeda Oncology Joins OmniComm's CRO Preferred Program and Signs Agreement for First Study

Veeda Oncology Joins OmniComm's CRO Preferred Program and Signs Agreement for First Study

FORT LAUDERDALE, FL, May 23, 2012 (MARKETWIRE via COMTEX) -- OmniComm Systems, Inc. OMCM +20.00%  , one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that Veeda Clinical Research Inc., also known as Veeda Oncology(R), has joined OmniComm's CRO Preferred Program, and as part of this program has signed an agreement to run their first study; a 27 month, phase I oncology trial. This complex trial will utilize the TrialMaster(R) EDC suite to manage their data collection, submission, and medical coding needs.

"We specifically selected TrialMaster due to their experience and expertise in conducting Oncology trials," said Sharon Jameson, VP, Global Clinical Operations. "We are also pleased to have OmniComm as a strategic partner and look forward to working with them on mutual projects in the future."

Veeda Oncology, a Global Oncology CRO capable of handling the rigors of phase I-IV programs, is dedicated to providing comprehensive clinical oncology research services internationally for the pharmaceutical and biotech industries. With offices in the US, Europe, India, and Malaysia, Veeda Oncology is in the unparalleled position to meet both the regional and global needs of sponsors.

"We look forward to working with this highly specialized CRO," said Stephen Johnson, President & Chief Operating Officer of OmniComm Systems. "We have a tremendous amount of Oncology experience and our TrialMaster solution is especially suited for these types of complex studies."

The addition of Veeda Oncology to the CRO Preferred Program brings the membership total to 48 CROs. This program offers CRO members exclusive benefits, such as a dedicated, hosted environment, sales and marketing support and training, all at a fixed, pay-as-you-go price for predictability and dependability. OmniComm understands how CROs do business and we have designed this program to align with how CROs contract with their clients.

About OmniComm

OmniComm Systems, Inc. ( ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

About Veeda Oncology

Veeda Oncology(R) is a global oncology company and a member of the Veeda CR family of companies. While Veeda Oncology is a growing company, our management team has over 20 years of clinical experience in the oncology field with facilities located in the US, Europe and India. These strategic locations provide a tremendous feet-on-the-ground perspective to best serve our sponsors. Our expertise has evolved from strong working relationships with pharmaceutical, as well as biotech, companies. Previous clients range from very large established companies to start-up biotechnology companies. Our mission is to provide outstanding oncology expertise that our clients require and expect to facilitate successful Phase I to Phase IV global programs.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE: OmniComm Systems, Inc.

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.